609 related articles for article (PubMed ID: 27102293)
1. Kirsten Ras* oncogene: significance of its discovery in human cancer research.
Tsuchida N; Murugan AK; Grieco M
Oncotarget; 2016 Jul; 7(29):46717-46733. PubMed ID: 27102293
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and Predictive Value of RAS Gene Mutations in Colorectal Cancer: Moving Beyond KRAS Exon 2.
Boeckx N; Peeters M; Van Camp G; Pauwels P; Op de Beeck K; Deschoolmeester V
Drugs; 2015 Oct; 75(15):1739-56. PubMed ID: 26347132
[TBL] [Abstract][Full Text] [Related]
3. Novel modalities in the treatment of patients with KRAS-mutated colorectal cancer.
Dimou A; Syrigos K; Saif MW
Anticancer Drugs; 2011 Jun; 22(5):384-91. PubMed ID: 21285867
[TBL] [Abstract][Full Text] [Related]
4. Intracellular Delivery of Anti-Kirsten Rat Sarcoma Antibodies Mediated by Polymeric Micelles Exerts Strong
Rafael D; Montero S; Carcavilla P; Andrade F; German-Cortés J; Diaz-Riascos ZV; Seras-Franzoso J; Llaguno M; Fernández B; Pereira A; Duran-Lara EF; Schwartz S; Abasolo I
ACS Appl Mater Interfaces; 2023 Mar; 15(8):10398-10413. PubMed ID: 36795046
[TBL] [Abstract][Full Text] [Related]
5. KRAS Pathways: A Potential Gateway for Cancer Therapeutics and Diagnostics.
Tripathi PK; Mittal KR; Jain N; Sharma N; Jain CK
Recent Pat Anticancer Drug Discov; 2024; 19(3):268-279. PubMed ID: 37038676
[TBL] [Abstract][Full Text] [Related]
6. Cycleave polymerase chain reaction method is practically applicable for V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)/V-raf murine sarcoma viral oncogene homolog B1 (BRAF) genotyping in colorectal cancer.
Yokota T; Shibata N; Ura T; Takahari D; Shitara K; Muro K; Yatabe Y
Transl Res; 2010 Aug; 156(2):98-105. PubMed ID: 20627194
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of carcinogenesis: the role of oncogenes, transcriptional enhancers and growth factors.
Spandidos DA
Anticancer Res; 1985; 5(5):485-98. PubMed ID: 3904595
[TBL] [Abstract][Full Text] [Related]
8. Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis.
Song QB; Wang Q; Hu WG
World J Gastroenterol; 2015 Apr; 21(14):4365-72. PubMed ID: 25892888
[TBL] [Abstract][Full Text] [Related]
9. Strategies to target energy metabolism in consensus molecular subtype 3 along with Kirsten rat sarcoma viral oncogene homolog mutations for colorectal cancer therapy.
Wang G; Wang JJ; Yin PH; Xu K; Wang YZ; Shi F; Gao J; Fu XL
J Cell Physiol; 2019 May; 234(5):5601-5612. PubMed ID: 30341899
[TBL] [Abstract][Full Text] [Related]
10. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
[TBL] [Abstract][Full Text] [Related]
11. Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy.
Laurent-Puig P; Pekin D; Normand C; Kotsopoulos SK; Nizard P; Perez-Toralla K; Rowell R; Olson J; Srinivasan P; Le Corre D; Hor T; El Harrak Z; Li X; Link DR; Bouché O; Emile JF; Landi B; Boige V; Hutchison JB; Taly V
Clin Cancer Res; 2015 Mar; 21(5):1087-97. PubMed ID: 25248381
[TBL] [Abstract][Full Text] [Related]
12. The Abundance of KRAS and RAS Gene Mutations in Cancer.
Stites EC
Methods Mol Biol; 2024; 2797():13-22. PubMed ID: 38570449
[TBL] [Abstract][Full Text] [Related]
13. Label-free and high-sensitive detection of Kirsten rat sarcoma viral oncogene homolog and epidermal growth factor receptor mutation using Kelvin probe force microscopy.
Jang K; Choi J; Park C; Na S
Biosens Bioelectron; 2017 Jan; 87():222-228. PubMed ID: 27566395
[TBL] [Abstract][Full Text] [Related]
14. Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade.
Umelo IA; De Wever O; Kronenberger P; Van Deun J; Noor A; Singh K; Teugels E; Chen G; Bracke M; De Grève J
Oncotarget; 2015 Aug; 6(24):20132-44. PubMed ID: 25992771
[TBL] [Abstract][Full Text] [Related]
15. EGFR fluorescence in situ hybridization-positive lung adenocarcinoma: incidence of coexisting KRAS and BRAF mutations.
Chiosea S; Shuai Y; Cieply K; Nikiforova MN; Dacic S
Hum Pathol; 2010 Aug; 41(8):1053-60. PubMed ID: 20381121
[TBL] [Abstract][Full Text] [Related]
16. Melting curve analysis for mutations of EGFR and KRAS.
Furugaki K; Yasuno H; Iwai T; Moriya Y; Harada N; Fujimoto-Ouchi K
Anticancer Res; 2014 Feb; 34(2):613-21. PubMed ID: 24510990
[TBL] [Abstract][Full Text] [Related]
17. KRAS: A Promising Therapeutic Target for Cancer Treatment.
Wu HZ; Xiao JQ; Xiao SS; Cheng Y
Curr Top Med Chem; 2019; 19(23):2081-2097. PubMed ID: 31486755
[TBL] [Abstract][Full Text] [Related]
18. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Douillard JY; Oliner KS; Siena S; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Williams R; Rong A; Wiezorek J; Sidhu R; Patterson SD
N Engl J Med; 2013 Sep; 369(11):1023-34. PubMed ID: 24024839
[TBL] [Abstract][Full Text] [Related]
19. KRAS and BRAF: drug targets and predictive biomarkers.
Vakiani E; Solit DB
J Pathol; 2011 Jan; 223(2):219-29. PubMed ID: 21125676
[TBL] [Abstract][Full Text] [Related]
20. Low incidence of oncogenic EGFR, HRAS, and KRAS mutations in seborrheic keratosis.
Georgieva IA; Mauerer A; Groesser L; Herschberger E; Aslanidis C; Dietmaier W; Landthaler M; Hafner C
Am J Dermatopathol; 2014 Aug; 36(8):635-42. PubMed ID: 23739246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
